多发性硬化症自体造血干细胞移植后月经周期恢复和女性生育能力。
Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis.
机构信息
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal-Child Health (DiNOGMI), University of Genova, Genova, Italy/Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal-Child Health (DiNOGMI), University of Genova, Genova, Italy.
出版信息
Mult Scler. 2021 Nov;27(13):2103-2107. doi: 10.1177/13524585211000616. Epub 2021 Mar 12.
Data on fertility after autologous hematopoietic stem cell transplantation (aHSCT) in women with multiple sclerosis (MS) are inconclusive. This study aims to report on post-aHSCT menstrual resumption in a multi-center MS-women cohort. Out of 43 women, 30 (70%) recovered menses after a mean time of 6.8 months. Older age (odds ratio (OR) = 0.5, < 0.0001) and previous pulsed cyclophosphamide (OR = 0.44, = 0.005) were independently associated with a reduced menstrual recovery probability. Conditioning regimens' intensity resulted not associated with post-procedure amenorrhea. Our results highlight younger age as significantly associated with menses recovery; proper fertility counseling for MS women candidated to aHSCT both prior- and post-transplantation is therefore warranted.
关于多发性硬化症（MS）女性自体造血干细胞移植（aHSCT）后生育能力的数据尚无定论。本研究旨在报告多中心 MS 女性队列中 aHSCT 后的月经恢复情况。在 43 名女性中，30 名（70%）在平均 6.8 个月后恢复了月经。年龄较大（优势比（OR）=0.5，<0.0001）和先前使用脉冲环磷酰胺（OR=0.44，=0.005）与月经恢复概率降低独立相关。预处理方案的强度与术后闭经无相关性。我们的结果强调了年龄与月经恢复显著相关；因此，对于有 aHSCT 适应证的 MS 女性，应在移植前后进行适当的生育咨询。
Zotero 插件